Back to News
Market Impact: 0.22
Evotec Biologics Begins Phase 1 Trial For Orthopoxvirus Antibody Program
Source: Nasdaq
Healthcare & BiotechProduct Launches
Evotec has initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal-antibody cocktail targeting orthopoxviruses. The trial marks an early clinical-development milestone for the program, but efficacy, safety, regulatory approval, and commercial potential remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EVO0.65
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine